Company Filing History:
1 out of 9 
1 out of 15 Years Active: 2022
Title: Bernardette Pilsl: Pioneering Innovations in Cancer Treatment
Introduction
Bernardette Pilsl is a notable inventor from Wenzenbach, Germany, recognized for her significant contribution to cancer research through her innovative work in pharmacology. She has been instrumental in developing targeted therapies that offer new hope for patients suffering from acute myeloid leukemia (AML).
Latest Patents
Bernardette Pilsl holds one patent titled "Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors." This invention pertains to small molecule compounds designed for use as FLT3 inhibitors, aimed specifically at combating various diseases, including acute myeloid leukemia. The patent provides detailed methodologies for synthesizing these compounds and outlines methods of treatment, emphasizing its potential impact on medical science.
Career Highlights
Throughout her career, Bernardette has accumulated substantial experience in academic and research settings. She has worked at the University of Regensburg and the University Medical Center of Johannes Gutenberg University Mainz, where her research has advanced the field of targeted cancer therapies.
Collaborations
In her pursuit of innovative solutions, Bernardette has collaborated with esteemed colleagues, including Siavosh Mahboobi and Andreas Sellmer. These partnerships have enriched her research endeavors and contributed to her successful innovations in pharmacology.
Conclusion
Bernardette Pilsl's dedication to her work and her innovative contributions have made a lasting impact on the field of cancer treatment. Her patent for FLT3 inhibitors highlights her commitment to developing effective therapies for serious diseases, establishing her as a prominent figure in the world of medical inventions.